Name: Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice (Video) | JoVE Journal
Uploaded: 2010-10-03T17:00:00.000+00:00
Duration: 5 min 10 s
Description: Learn intracranial orthotopic allografting of medulloblastoma cells in immunocompromised mice to study tumor formation and progression. This method enables researchers to model secondary brain tumors in vivo.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This study was supported by grants from the Vanderbilt-Ingram Cancer Center Support Grant (P30 CA068485), the Childhood Brain Tumor Foundation and the National Institutes of Health (NS042205).

1. Micro-dissection of Tumor-bearing Cerebellum and Dissociation of Tumor Tissue
<ol>
<li>Retrieval of tumor tissue
<ol>
<li> Sick mice bearing medulloblastoma are often runted, and display hydrocephaly and typical neurological symptoms, including posterior paralysis and failure to regain posture when overturned. To retrieve tumor tissue, euthanize mice by carbon dioxide inhalation. It is imporant not to perform cervical dislocation, a procedure that generates pressure to the posterior skull and can compromise tumor tissue integrity.</li>
<li> Decapitation is performed immediately after death using a pair of scissors, removing hair and muscle tissue as much as possible for good visualization of the skull. Clean the surface of the skull with Kimwipe soaked with 95% ethanol.</li>
<li>Use fine scissors to cut an opening along the midline of the skull, and remove skull tissue using fine tweezers, at which point the whole brain including tumor-bearing cerebellum is exposed.</li>
<li>While the cerebella of healthy adults display well-defined hemispheres and vermis, the cerebella of tumor-bearing mice are often enlarged, amorphous with a smooth surface and conspicuous blood vessels. Using sterile techniques, retrieve the cerebellar tumor using tweezers and place in ice-cold phosphate buffered saline (PBS) without Mg2+ and Ca2+.</li>
</ol>
</li>
</ol>
Note: all instruments are disinfected in 95% ethanol and steam autoclaved before use.
<ol start="2">
<li>Dissociation of tumor tissue
<ol>
<li> Transfer the tumor tissue from PBS to 50% Accutase (diluted in PBS) that is about 4 times the volume of the tumor tissue, mince the tissue with fine scissors for 3 minutes at room temperature, followed by incubation at 37°C for 4 minutes, after which the tissue undergoes repetitive pipeting with a 1-mL Pipetman for an additional 3 minutes. This method should yield a mixture of single cells and small cellular aggregates.</li>
<li> Dilute the cellular suspension 3-fold with PBS and centrifuge for 5 minutes at 1000xg to pellet the cells. (The procedures above have been described in "Isolation, enrichment and maintenance of medulloblastoma stem cells", JoVE in press)</li></ol></li></ol>
Resuspend the cell pellet in freshly prepared neural stem cell medium consisting of Neurobasal medium with glutamine, Penicillin-Streptomycin, N2, B27, human EGF (25 ng/mL) and basic FGF (25 ng/mL). Calculate the cell density of the solution and make appropriate further dilutions with additional neural stem cell medium such that one can load 4 μL of solution with an appropriate number of dissociated tumor cells, e.g. 5x105, into a sterile bevel-tipped 10μL syringe. The exact number of cells to be inoculated should be determined by the researcher according to specific experimental requirements. Keep the cell solution in a mini 200μL microcentrifuge tube (PCR tube) on ice.
2. Anesthetic Procedures for the Recipient Mice
For the surgical procedure, a disinfected area dedicated to rodent surgery is needed for the duration of the procedure. Ideally, set up a long bench with separate but adjoining areas for animal preparation, operating field and animal recovery. Surgical gloves, not exam gloves, are required for the surgery. Aseptic technique is maintained by holding gloved hands above the waist and used only to handle sterile objects from a dry sterile surface.
<ol>
<li> A mixture of ketamine (100 mg ketamine per 1 kg of mouse weight) and xylazine (10 mg xylazine per 1 kg of mouse weight) is used for anesthesia. Administer the anesthetics intraperitoneally.</li>
<li>It generally takes 3-5 minutes for the anesthetics to take full effect. Determine whether a mouse is fully anesthetized by toe/tail pinch. Place a small amount of ophthalmic ointment on the eyes of the mouse. Bring the fully anesthetized mouse to the operating area, constantly monitoring to make sure that the mouse is breathing normally.</li>
</ol>
3. Intracranial Grafting of the Tumor Cells
<ol>
<li>Shave the dorsal posterior head region of the mouse, using a hair clipper, to reveal the posterior skull above the midbrain and cerebellum.</li>
<li>Apply Betadine solution on the exposed scalp using a cotton tip applicator, followed by wiping with an alcohol pad. Repeat these two sterilizing steps two times.</li>
<li>Make a quarter-inch incision in the posterior scalp using a sterilized scalpel. Drill a 0.5 mm burr hole 2 mm to the right and 2 mm posterior to the lambda using a sterile dental drill.</li>
<li>Place the mouse onto a stereotactic frame by hooking its incisors onto the frame hold. Carefully descend and position the bevel-tipped 10 μL syringe loaded with 4 μL of tumor cell solution into the burr hole. Once the bevel of the syringe needle is below the skull surface, descend for another 3 mm and then ascend for 0.5 mm. Slowly inject the desired amount of tumor cells, with a steady force in a 30 second time frame, into the cerebellum of the recipient. Leave the needle in its place after completion of injection for an additional two minutes. Then remove the needle and syringe. Clip the wound using an autoclip.</li>
<li>Keep the mouse on a warming blanket after the surgery to help maintain its body temperature. 
Mobility and respiratory patterns will be observed continuously. Once the mouse recovers from anesthesia, place it back in a sterile housing cage. Monitor daily for food and water intake, behavior, grooming, and red staining of the eyes. Inspect for signs of infection at the incision site. Remove the autoclips on day 7 post surgery. 
Maintain the mice for an average of 2-6 months and sacrifice those displaying typical medulloblastoma symptoms for further studies.</li>
</ol>
4. Representative Results
Secondary medulloblastomas developed in recipient mice highly resembled those of the primary tumors. The cerebella bearing secondary tumors were often enlarged, amorphous with ectopic blood vessels apparent when viewed as whole-mounts. Immunohistochemical analyses of the secondary tumor tissue revealed that the tumor cells are highly proliferative, express strong SmoM2-YFP and markers of cerebellar granule neuron precursors, such as Math1 and Pax6. When dissociated and cultured using reported methods ("Isolation, enrichment and maintenance of medulloblastoma stem cells", JoVE in press), the secondary medulloblastoma tumor cells can be expanded rapidly, express multiple stem cell markers, are clonogenic and can further initiate tumor formation when transplanted into additional immunocompromised recipients.
 <img src="/files/ftp_upload/2153/2153fig1.jpg" alt="Pathology micrographs of tumor sections with hematoxylin, Ki67, YFP staining for cell analysis." data-altupdatedat="1785211204000" data-alt="Figure 1"> 
Figure 1. Typical whole-mount and sectional views of a secondary medulloblastoma tissue 
A typical example of secondary medulloblastoma tissue developed 26 days after injection of 5x105 primary tumor cells. Hematoxylin staining reveals the typical cellular morphology of medulloblastoma, including high nuclear/cytoplasmic ratio and nuclear polymorphism. These secondary tumor cells are highly proliferative as indicated by Ki67 expression and they also robustly express membranous SmoM2-YFP.
 <img src="/files/ftp_upload/2153/2153fig2.jpg" alt="Cell migration observation under a microscope; cluster formation comparison in scientific analysis." data-altupdatedat="1785211204000" data-alt="Figure 2"> 
Figure 2. Secondary medulloblastoma cells can be cultured and expanded in vitro 
Using the protocol described for primary mouse medulloblastoma cells ("Isolation, enrichment and maintenance of medulloblastoma stem cells", JoVE in press), these secondary medulloblastoma cells can be cultured and expanded for multiple passages. The picture shows the same representative tumor colony cultured at 4 days and 14 days. The cultured tumor cells are bipolar, elongated with scant cytoplasm and often radiate from a dense core of cellular aggregate. They do not exhibit growth contact inhibition. The small round cells are red blood cells.

<ol><li>Schuller, U. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Acquisition+of+granule+neuron+precursor+identity+is+a+critical+determinant+of+progenitor+cell+competence+to+form+Shh-induced+medulloblastoma%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma.</a> Cancer Cell. 14, 123-134 (2008).</li>
<li>Yang, Z. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Medulloblastoma+can+be+initiated+by+deletion+of+Patched+in+lineage-restricted+progenitors+or+stem+cells%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells.</a> Cancer Cell. 14, 135-145 (2008).</li>
<li>Kessler, J. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((N-myc+alters+the+fate+of+preneoplastic+cells+in+a+mouse+model+of+medulloblastoma%5BTitle%5D)+AND+%22Genes+Dev%22%5BJournal%5D)">N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma.</a> Genes Dev. 23, 157-170 (2009).</li>
<li>Flora, A., Klisch, T. J., Schuster, G., Zoghbi, H. Y., Y, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Deletion+of+Atoh1+disrupts+Sonic+Hedgehog+signaling+in+the+developing+cerebellum+and+prevents+medulloblastoma%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Deletion of Atoh1 disrupts Sonic Hedgehog signaling in the developing cerebellum and prevents medulloblastoma.</a> Science. 326, 1424-1427 (2009).</li>
<li>Salsano, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Expression+of+the+neurogenic+basic+helix-loop-helix+transcription+factor+NEUROG1+identifies+a+subgroup+of+medulloblastomas+not+expressing+ATOH1%5BTitle%5D)+AND+%22Neuro+Oncol%22%5BJournal%5D)">Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1.</a> Neuro Oncol. 9, 298-307 (2007).</li>
</ol>

No conflicts of interest declared.

Several critical factors to ensure successful medulloblastoma cell allografting that yields secondary tumor formation are as follows: First, use only 50% Accutase for tissue dissociation and do not over-digest the tissue as prolonged enzyme treatment leads to significant reduction in cell viability. Also use only the 1 mL size Pipetman as smaller tips can also generate physical damage to the dissociated cells. It is fine to have a mixture of single cells and small aggregates for allografting. Second, mix and equilibrate...

<table><tbody><tr><td>Neurobasal medium</td><td>Invitrogen</td><td>21103049</td><td></td></tr><tr><td>hEGF</td><td>Invitrogen</td><td>PHG0311</td><td>25ng/ml</td></tr><tr><td>bFGF</td><td>Invitrogen</td><td>PHG0023</td><td>25ng/ml</td></tr><tr><td>N2</td><td>Invitrogen</td><td>17502048</td><td>1X</td></tr><tr><td>B27(-RA)</td><td>Invitrogen</td><td>12587010</td><td>1X</td></tr><tr><td>Accutase</td><td>Invitrogen</td><td>A1110501</td><td>50% </td></tr><tr><td>Glutamine</td><td>Invitrogen</td><td>25030081</td><td>2mM</td></tr><tr><td>Stereotaxic instrument</td><td>Stoelting Co.</td><td>51730</td><td></td></tr><tr><td>Foredom flexible shaft drill, hang-up style</td><td>Stoelting Co.</td><td>58650</td><td></td></tr><tr><td>Large probe holder</td><td>Stoelting Co.</td><td>51633</td><td></td></tr><tr><td>10 &amp;mu;L syringe, 26 ga., bevel tip</td><td>Stoelting Co.</td><td>51105</td><td></td></tr><tr><td>Drill bit .75mm</td><td>Stoelting Co.</td><td>51455-3</td><td></td></tr></tbody></table>

intracranial orthotopic allografting of medulloblastoma cells in immunocompromised mice

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Medulloblastoma is the most common pediatric tumor of the nervous system. A large body of animal studies has focused on cerebellar granule neuron precursors (CGNPs) as the cell-of-origin for medulloblastoma1-4. However, the diverse clinical presentations of medulloblastoma subtypes in human patients (nodular, desmoplastic, classical and large cell/anaplastic), and the fact that medulloblastoma is found in a subset of human patients with no ectopic expression of CGNP marker5, suggest that the cellular and molecular origins of medulloblastoma are more complex and far from being completely deciphered. Therefore, it is essential to determine whether there is an alternative medulloblastoma tumor cell-of-origin based on which cell-type specific therapeutic modality can be developed. To this end, intracranial orthotopic allografting of genetically marked tumor cell types followed by subsequent analyses of secondary tumor development in recipients will allow determination of the cellular origin of tumor-initiating cells. Here we describe the experimental protocol for intracranial orthotopic allografting of medulloblastoma cells derived from primary tumor tissue, and this procedure can also be used for transplanting cells from established cell lines.

This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, and subsequent allografting of the tumor cells into immunocompromised recipient mice in order to initiate secondary medulloblastoma.

Medulloblastoma is the most common pediatric tumor of the nervous system. A large body of animal studies has focused on cerebellar granule neuron ...

The overall goal of this procedure is to author topically allograft medulloblastoma tumor cells into an immunocompromised host to initiate a secondary tumor. This is accomplished by first associating primary medulloblastoma tissue into single cells and small cellular aggregates. The second step of the procedure is to prepare immunocompromised mice for intracranial injection.The third step of the procedure is performing microinjection of tumor cells into the host cerebellum. The final steps of the procedure are maintaining and observing the tumor cell grafted hosts. Ultimately, results can be obtained that show secondary medulloblastoma formation in the hosts by the displayed neurological symptoms and histological analysis.This technique can help answer key questions in cancer biology, such as determining the cellular origin of a tumor and factors important for initiating and propagating tumors, Microdisect and dissociate tumor tissue from m sparing medulloblastoma as described in the companion video article, isolation, enrichment and maintenance of medulloblastoma cell lines dilute the tumor cell suspension in neuro stem cell medium, so that four microliters of solution contains the appropriate number of dissociated tumor cells. Here, five times 10 to the six cells. Keep the dilute cell suspension in a 200 microliter micro centrifuge tube on ice.Use a hair clipper to shave the dorsal posterior head region of an anesthetized immunocompromised host mouse revealing the posterior skull. Apply Betadine solution to the exposed scalp, followed by wiping with an alcohol pad. Repeat these two sterilizing steps twice.Use a sterile scalpel to make a one-quarter inch incision in the posterior scalp. Use a sterile dental drill to drill a 0.5 millimeter bur hole, two millimeters to the right and two millimeters posterior to lambda. Hook the host mouses in sizes onto a stereotactic frame.To secure the mouse load a bevel Tip 10 microliter syringe. With four microliters of tumor cell suspension, secure the syringe to a micro manipulator on the frame. Under the microscope, carefully descend and position the needle tip into the bur hole.When the bevel of the syringe is below the skull surface, descend for three millimeters. Then back up the 0.5 millimeters to create a space in between the tip of the needle and the cerebellar tissue. Slowly with steady force over the course, 30 seconds, inject four microliters of the tumor cell suspension into the cerebellum of the host mouse.Leave the needle in place for two minutes. Remove the needle and the syringe. Use a sterile auto clip to seal the wound.Allow the mouse to recover on a warming blanket. After surgery, place the mouse back in a sterile housing cage and monitor behavior and for infection at the injection site. Seven days after surgery, remove the auto clip.Mice will display typical medulloblastoma symptoms, symptoms between two and six months. Here is a typical example of secondary medulloblastoma tissue developed 26 days after injection of five times 10 to the five primary tumor cells. Hemat toin staining reveals the typical cellular morphology of medulloblastoma, including high nuclear to cytoplasmic ratio and nuclear polymorphism.These secondary tumor cells are highly proliferative, as indicated by KI 67 expression, and they also robustly express membranous smoothened M two YFP. Using the companion protocol for primary mouse modelo blasts, stoma cells. These secondary modelo blasts stoma cells can be cultured and expanded for multiple passages.Red arrows point to some red blood cells. Here is the same Representative tumor colony cultured at four days and at 14 days. The cultured tumor cells are bipolar, elongated with scan cytoplasm, and often radiate from a dense core of cellular aggregates.While attempting these procedures, it's important to create a proper space in between the cere tissue and the tip of injection needle by sending it 0.5 millimeters after lowering it three millimeters beneath the skull surface.

intracranial-orthotopic-allografting-medulloblastoma-cells

Research

JoVE Journal

Neuroscience

The purpose of this article is to describe the use of an orthotopic glioblastoma model for chemoradiation studies. This article will go though cell processing, implanting, and radiotherapy of the mouse using an intracranial model.

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

This video demonstrates implantation of tumor cells in the mouse brain by performing intracranial injection.

Intracranial Orthotopic Model: A Procedure to Implant Cancer Cells in Mouse Brain

Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models.

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

We have established a cortical orthotopic glioblastoma model in mice for intravital two-photon microscopy that recapitulates the biophysical constraints normally at play during the growth of the tumor. A chronic glass window replacing the skull above the tumor enables the follow-up of the tumor progression over time by two-photon microscopy.

An Orthotopic Glioblastoma Mouse Model Maintaining Brain Parenchymal Physical Constraints and Suitable for Intravital Two-photon Microscopy

Phenotypically wild-type astrocytes and neural stem cells harvested from mice engineered with floxed, conditional oncogenic alleles and transformed via viral Cre-mediated recombination can be used to model astrocytoma pathogenesis in vitro and in vivo by orthotopic injection of transformed cells into brains of syngeneic, immune-competent littermates.

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Stem cells are promising therapeutic carriers to treat brain tumors due to their intrinsic tumor tropism. Non-invasive intranasal stem cell delivery bypasses the blood brain barrier and demonstrates strong potential for clinical translation. This article summarizes the basic principles of intranasal stem cell delivery in a mouse model of glioma.

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Tumor-seeking therapeutic mesenchymal stem cells (MSCs) show promise as a treatment for invasive glioblastoma. Optimal transplantation involves delivery of MSCs into the tumor resection cavity on scaffolds. Here, preclinical techniques to study MSC treatment of glioblastoma are provided including: image-guided tumor resection; implantation of MSC-seeded scaffolds; and postoperative therapy tracking.

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Here, we present a protocol for the preparation and the stereotaxic administration of allogeneic human lymphocytes in immunodeficient mice carrying orthotopic human primary brain tumors. This study provides a proof-of-concept for both the feasibility and the antitumor efficacy of intrabrain-delivered cellular immunotherapies.

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Here, we describe a preclinical orthotopic mouse model for GBM, established by intracranial injection of cells derived from genetically engineered mouse model tumors. This model displays the disease hallmarks of human GBM. For translational studies, the mouse brain tumor is tracked by in vivo MRI and histopathology.

Translational Orthotopic Models of Glioblastoma Multiforme

The development of orthotopic pediatric brain tumor models requires meticulous precision, using a stereotaxic device to implant cancer cells precisely. The methodology presented here outlines the steps involved in preparing brain tumor cells, performing intracranial injections, and implementing a post-operative monitoring system to assess brain tumor engraftment.

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

The goal of this protocol is to provide researchers with a highly reproducible technique for intracranial implantations.

Stereotactic Intracranial Implantation of Glioblastoma Patient-derived Xenograft Cell Lines in Mice

Learn intracranial orthotopic allografting of medulloblastoma cells in immunocompromised mice to study tumor formation and progression. This method enables researchers to model secondary brain tumors in vivo.

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Explore More Videos